Avalo Therapeutics, Inc. (NASDAQ:AVTX) is among the best low priced stocks to get rich in 2026. On June 12, BofA started coverage on Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a Buy rating and a price target of $35. According to the firm, the company is a "cleaner, single-asset immunology story" following the positive Phase 2 data in hidradenitis suppurativa. If the company's lead product, abdakibart, is compared with alternative drugs, the former may provide a more convenient monthly dosing schedule and greater impact on disease outcomes, the firm added.
BofA views the investment case as "a differentiated IL-1β antibody in HS, a large undertreated market, and a balance sheet with runway through next major data readout into 2029e after ~$405M net proceeds."
The company's one-year return is what catches the eye, with an impressive 183% market outperformance. This doesn't stop here as the company's future looks equally promising. With a bullish stance from all 14 ****** ysts covering the stock, Avalo Therapeutics, Inc. (NASDAQ:AVTX) has a 1-year upside potential of 195.92%. No wonder AVTX is among the best low-priced stocks to get rich in 2026.
Avalo Therapeutics, Inc. (NASDAQ:AVTX), incorporated in 2011, is a Pennsylvania-based clinical-stage biotechnology company that provides solutions for immune-mediated inflammatory diseases. The company's lead candidate is AVTX-009.
While we acknowledge the potential of AVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
BofA views the investment case as "a differentiated IL-1β antibody in HS, a large undertreated market, and a balance sheet with runway through next major data readout into 2029e after ~$405M net proceeds."
The company's one-year return is what catches the eye, with an impressive 183% market outperformance. This doesn't stop here as the company's future looks equally promising. With a bullish stance from all 14 ****** ysts covering the stock, Avalo Therapeutics, Inc. (NASDAQ:AVTX) has a 1-year upside potential of 195.92%. No wonder AVTX is among the best low-priced stocks to get rich in 2026.
Avalo Therapeutics, Inc. (NASDAQ:AVTX), incorporated in 2011, is a Pennsylvania-based clinical-stage biotechnology company that provides solutions for immune-mediated inflammatory diseases. The company's lead candidate is AVTX-009.
While we acknowledge the potential of AVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
1 month ago
